Advertisement

Sodium Tanshinone II A Sulfonate for Coronary Heart Disease: A Systematic Review of Randomized Controlled Trials

  • Mei-li Yu
  • Si-ming Li
  • Xiang Gao
  • Jin-gen Li
  • Hao XuEmail author
  • Ke-ji ChenEmail author
Evidence-Based Integrative Medicine
  • 36 Downloads

Abstract

Objective

To assess whether an adjunctive therapy of Sodium Tanshinone II A Sulfonate Injection (STS) is effective and safe in improving clinical outcomes in patients with coronary heart disease (CHD).

Methods

literature search was conducted through PubMed, the Cochrane Library, Knowledge Infrastructure Databases (CNKI), Chinese Biomedical Literature Database (SinoMed), Chinese Science and Technology Periodical Database (VIP) and Wanfang Database up to August 2017. Randomized controlled trials (RCTs) comparing STS with placebo or no additional treatments on the basis of standard conventional medicine therapies were included. The outcomes were all-cause mortality, major acute cardiovascular events (MACEs), cardiac function and inflfl ammatory factors. The risk of bias assessment according to the Cochrane Handbook was used to evaluate the methodological quality of the included trials. Revman 5.3 software was used for data analyses.

Results

A total of 22 RCTs involving 1,873 participants were included. All of the trials used STS as adjunctive treatment to standard conventional medicine therapy. Due to the poor quality of methodologies of most trials, only limited evidence showed that a combination of STS with percutaneous coronary intervention (PCI) or thrombolytic therapy (TT) might be more effective on reduction of all cause death rate than TT alone [risk ratio (RR) 0.25, 95% confifi dence interval (CI) 0.07 to 0.87] or PCI alone (RR 0.42, 95% CI 0.04 to 4.36). The results of 6 trials comparing STS plus TT with TT alone showed that the addition of STS signififi cantly reduced the incidence of cardiac shock (RR 0.35, 95% CI 0.14 to 0.86), heart failure (RR 0.41, 95% CI 0.20 to 0.83) and arrhythmia (RR 0.21, 95% CI 0.12 to 0.46). STS combined with TT also showed a superior effect on cardiac function and inflammatory factor. No severe adverse event was reported related to STS.

Conclusions

As an adjunctive therapy, STS combined with standard conventional medicine seems to be more effective on all-cause mortality or MACEs than conventional medicine treatment alone with less side effects. However, we cannot make a fifi rm conclusion due to low quality of inclusion trials. Well-designed trials with high methodological quality are needed to validate the effect of STS for CHD patients.

Keywords

Tanshinone II A coronary heart disease meta-analysis systematic review 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Supplementary material

11655_2018_2556_MOESM1_ESM.docx (51 kb)
Supplementary material, approximately 52 KB.

References

  1. 1.
    Dalen JE, Alpert JS, Goldberg RJ, Weinstein RS. The epidemic of the 20th century: coronary heart disease. Am J Med 2014;127:807–812.CrossRefPubMedGoogle Scholar
  2. 2.
    Wong ND. Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev Cardiol 2014;11:276–289.CrossRefPubMedGoogle Scholar
  3. 3.
    Napoli C, Lerman LO, de Nigris F, Gossl M, Balestrieri ML, Lerman A. Rethinking primary prevention of atherosclerosisrelated diseases. Circulation 2006;114:2517–2527.CrossRefPubMedGoogle Scholar
  4. 4.
    Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713–1722.CrossRefPubMedGoogle Scholar
  5. 5.
    Chen KJ, Shi DZ, Xu H, Lü SZ, Li TC, Ke YN, et al. XS0601 reduces the incidence of restenosis: a prospective study of 335 patients undergoing percutaneous coronary intervention in China. Chin Med J 2006;119:6–13.PubMedGoogle Scholar
  6. 6.
    Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 2008;101:1689–1693.CrossRefPubMedGoogle Scholar
  7. 7.
    Li X, Zhang J, Huang J, Ma A, Yang J, Li W. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of Qili Qiangxin Capsules in patients with chronic heart failure. J Am Coll Cardiol 2013;62:1065–1072.CrossRefPubMedGoogle Scholar
  8. 8.
    Wang MZ, Yan FS, Gao FY. Analysis of high performance liquid chromatography on three tanshinones from Salviamilt iorrhizae. J Pharm Ana lysis 1985;5:348–350.Google Scholar
  9. 9.
    Shang Q, Xu H, Huang L. Tanshinone II A: A promising natural cardioprotective agent. Evid Based Complement Alternat Med 2012;2012:716459.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Chen Z, Xu H. Anti-inflammatory and immunomodulatory mechanism of tanshinone II A for atherosclerosis. Evid Based Complement Alternat Med 2014:2014:267976.Google Scholar
  11. 11.
    Higgins J, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.0.2 ed. The Cochrane Collaboration 2009.Google Scholar
  12. 12.
    Du QM, Wang CX. Effects of sodium tanshinone II A sulfonate on arrhythmia induced by myocardial ischemiareperfusion. Chin J Geriatric Heart Brain Vessel Dis (Chin) 2011;13:349–351.Google Scholar
  13. 13.
    Fan LY, Yang J. Impact of tanshinone II A sulfonic acid natrium on blood lipid metabolism, serum inflammatory cytokines levels and cardiac function in patients with acute myocardial infarction. Pract J Cardiac Cerebral Pneumal Vascular Dis (Chin) 2015;23:14–17.Google Scholar
  14. 14.
    Gan SY, Rong RC, Li B. Effects tanshinone II A on infl ammatory cytokines and oxidative stress of the patient with acute coronary syndrome. Pharm Clin Chin Materia Medica (Chin) 2014; 30:163–166.Google Scholar
  15. 15.
    He Y. Efficacy and safety of Danshen Injection in treating patients with unstable angina pectoris of qi defi ciency and blood stasis type in perioperative period of interventional therapy: a clinical study of the efficacy and safety of II A [Dissertation]. Urumqi: Xinjiang Medical University; 2016.Google Scholar
  16. 16.
    Huang PH. Protection of sodium tanshinone II A sulfonate on myocardium reperfusion injury after AMI thrombolysis. Med Frontier (Chin) 2012;20:350–351.Google Scholar
  17. 17.
    Li CR, Gan SY, Huang HX. Study on the curative effect of sodium tanshinone II A sulfonate in patient with acute coronary syndrome and its infl uence on infl ammatory cytokines. Modern J Integr Tradit Chin West Med (Chin) 2015;24:2284–2286.Google Scholar
  18. 18.
    Li JC, Sun ZG. Influence of Tanshinone II A Sulfonate Injection combined with simvastatin on infl ammatory factor in patients with coronary heart disease. Chin Primary Health Care (Chin) 2015;29:111–112.Google Scholar
  19. 19.
    Li RJ, Zhang KS. Infl uence of Tanshinone II A Sulfonate Sodium Injection on latelet activation in patients with unstable angina pectoris of coronary atherosclerotic heart disease with blood stasis syndrome. China Pharmaceuticals (Chin) 2017;29:63–65.Google Scholar
  20. 20.
    Li SM, Jiao Y, Wang H, Shang QH, Lu F, Huang L, et al. Sodium tanshinone II A sulfate adjunct therapy reduces highsensitivity C-reactive protein level in coronary artery disease patients: a randomized controlled trial. Sci Rep 2017;7:17451.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Li Y. Effect of tanshinone II A on the cardiac function and inflammatory cytokines in patients with acute myocardial infarction. J Hainan Med Univ (Chin) 2016;22:1933–1935.Google Scholar
  22. 22.
    Liu PF, Zhang YM, Tang JW, Li HL. The effect and clinical signifi cance of Tanshinone Injection on plasma NT-proBNP in acute myocardial infarction. Chin J Diffi cult Complicated Cases (Chin) 2009;8:327–329.Google Scholar
  23. 23.
    Luan T, Pan T. Effects of Tanshinone Injection on myocardial ischemia reperfusion injury and different syndromes of TCM. Chin J Integr Med Cardio-/Cerebrovas Dis (Chin) 2012;10:524–526.Google Scholar
  24. 24.
    Qi H, Zhao X, Li YF. Study on the curative effect of Sodium Tanshinone II A Sulfonate Injection in treating acute myocadiac infarction. China Med Herald (Chin) 2006;3:22–23.Google Scholar
  25. 25.
    Qin S. C1inical efficacy of tanshinone plus atorvastatin against CHD. Clin J Chin Med (Chin) 2012;4:25–27.Google Scholar
  26. 26.
    Tang XJ. Clinical study of coronary heart disease and angina pectoris with blood stasis syndrome treated by Sodium Tanshinone II A Sulfonate Injection [Dissertation]. Beijing: Beijing University of Chinese Medicine; 2014.Google Scholar
  27. 27.
    Wei Q, Shen XJ. Effects of tanshinone II on clinical symptoms and vascular aging factor in angina pectoris of coronary heart disease patients. J Basic Chin Med (Chin) 2014;20:783–785.Google Scholar
  28. 28.
    Xie Q, Zhang XJ. 31 cases of clinical observation research of Sodium Tanshinone II A Sulfonate Injection in patients with angina after infarction. Chin J Ethnomed Ethnopharm (Chin) 2016;25:126–128.Google Scholar
  29. 29.
    Xu T, Zhang Z, Wang JP, Feng FY, Liu X. Effect of sodium tanshinone II A sulfonate combined with atorvastatin on TL R4 inflammatory signal pathway and immune function of patients with coronary heart diseases. Hebei Med J (Chin) 2015;37:3365–3368.Google Scholar
  30. 30.
    Zhang XR, Wang LJ, Liu HJ, Dong W, Guo YB. The impact of Tan treatment on haemodynamics and blood lipid of acute myocardial infarction patients. J Guizhou Med Univ (Chin) 2014;39:379–382.Google Scholar
  31. 31.
    Chang JY, Wang SZ, and Yan JX. Impact of tanshinone II A on cardiac function and hs-CRP, TNF-α, IL-6 Levels of patients with acute myocardial infarction. China Med Pharm (Chin) 2016;6:142–145.Google Scholar
  32. 32.
    Chen J. Influence of Sodium Tanshinone II A Sulfonate Injection in thrombolytic therapy of acute myocardial infarction patients. Tianjin Pharm (Chin) 2007;19:35–36.Google Scholar
  33. 33.
    Chu C, Tao ZG, Fan YJ. Effect of Sodium Tanshinone II A Sulfonate Injection on the serum infl ammatory factors in acute coronary syndrome. Shandong Med J (Chin) 2014;54:67–68.Google Scholar
  34. 34.
    Yan GP, Zhu CL, Sun YQ. Meta-analysis of Salvianolate Injection in the treatment of unstable angina pectoris. J Emerg Trad Chin Med 2015;5:771–774.Google Scholar
  35. 35.
    Zhang D, Wu J, Liu S, Zhang X, Zhang B. Salvianolate Injection in the treatment of unstable angina pectoris: A systematic review and meta-analysis. Medicine (Baltimore) 2016;95:1–9.CrossRefGoogle Scholar
  36. 36.
    Tan D, Wu JR, Zhang XM, Liu S, Zhang B. Sodium Tanshinone II A Sulfonate Injection as adjuvant treatment for unstable angina pectoris: a meta-analysis of 17 randomized controlled trials. Chin J Integr Med 2018;24:1–5.CrossRefGoogle Scholar
  37. 37.
    Wang X. Progress of pharmacological research and clinical application of tanshinone II A," Guangming J Chin Med (Chin) 2011;26:1514–1517.Google Scholar
  38. 38.
    Bai FM. Clinical application progress of sodium tanshinone II—a sulfonate. China Pharm (Chin) 2012;23:1770–1772.Google Scholar
  39. 39.
    Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ, CANTOS Trial Group. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet 2018;391:319–328.CrossRefPubMedGoogle Scholar
  40. 40.
    Libby P. Interleukin-1 Beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond. J Am Coll Cardiol 2017;70:2278–2289.CrossRefPubMedGoogle Scholar
  41. 41.
    Robertson AL, Holmes GR, Bojarczuk AN, Burgon J, Loynes CA, Chimen M, et al. A zebrafsh compound screen reveals modulation of neutrophil reverse migration as an antiinfammatory mechanism. Sci Transl Med 2014;6:225ra29.CrossRefGoogle Scholar

Copyright information

© Chinese Association of the Integration of Traditional and Western Medicine 2018

Authors and Affiliations

  1. 1.Graduate SchoolBeijing University of Chinese MedicineBeijingChina
  2. 2.Cardiovascular Diseases Center, Xiyuan HospitalChina Academy of Chinese Medical SciencesBeijingChina
  3. 3.Tieying Hospital of Fengtai DistrictBeijingChina

Personalised recommendations